acido alfa lipoico

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• age-related cognitive decline [Insufficient Evidence]
• age-related macular degeneration [Insufficient Evidence]
• age-related testosterone deficiency [Insufficient Evidence]
• alcoholic liver disease [Possibly Ineffective]
• altitude sickness [Possibly Ineffective]
• Alzheimer disease [Insufficient Evidence]
• anthracycline-induced cardiotoxicity [Insufficient Evidence]
• arthralgia, aromatase inhibitor-induced [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• atrial fibrillation [Insufficient Evidence]
• back pain [Insufficient Evidence]
• beta-thalassemia [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• burning mouth syndrome [Insufficient Evidence]
• CABG [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cardiovascular disease [Insufficient Evidence]
• carpal tunnel syndrome [Insufficient Evidence]
• cataracts [Insufficient Evidence]
• cervical dysplasia [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• CKD [Insufficient Evidence]
• dementia, HIV/AIDS-related [Possibly Ineffective]
• diabetes mellitus [Possibly Ineffective]
• diabetic nephropathy [Insufficient Evidence]
• diabetic neuropathy [Possibly Effective]
• diabetic retinopathy [Possibly Ineffective]
• dry eye disease [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• erectile dysfunction [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• glaucoma [Insufficient Evidence]
• heart failure [Insufficient Evidence]
• hemorrhoids [Insufficient Evidence]
• hepatotoxicity, toxin-induced [Insufficient Evidence]
• herniated disc [Insufficient Evidence]
• HIV/AIDS [Insufficient Evidence]
• HTN [Insufficient Evidence]
• hyperlipidemia [Possibly Effective]
• hyperprolactinemia, antipsychotic-induced [Insufficient Evidence]
• hypertriglyceridemia [Insufficient Evidence]
• hypotension, orthostatic [Insufficient Evidence]
• impaired glucose tolerance [Insufficient Evidence]
• infertility in patients of childbearing potential [Insufficient Evidence]
• interstitial cystitis [Insufficient Evidence]
• Lyme disease [Insufficient Evidence]
• male infertility [Insufficient Evidence]
• metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
• metabolic effects, antipsychotic-induced [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• migraine prophylaxis [Insufficient Evidence]
• miscarriage prevention [Insufficient Evidence]
• muscle strength [Insufficient Evidence]
• mushroom toxicity (Amanita phalloides) [Insufficient Evidence]
• neck pain [Insufficient Evidence]
• nephropathy prophylaxis, contrast-induced [Possibly Ineffective]
• neuropathic pain [Insufficient Evidence]
• obesity [Possibly Effective]
• osteoarthritis [Insufficient Evidence]
• pain, chronic [Insufficient Evidence]
• periodontitis [Insufficient Evidence]
• peripheral arterial disease [Insufficient Evidence]
• peripheral neuropathy, chemo-induced [Insufficient Evidence]
• persistent olfactory dysfunction, post-COVID-19 [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• preterm labor prevention [Insufficient Evidence]
• radiation exposure [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• sciatica [Insufficient Evidence]
• skin aging [Insufficient Evidence]
• tinnitus [Insufficient Evidence]
• vertigo [Insufficient Evidence]
• vitiligo [Insufficient Evidence]
• Wilson disease [Insufficient Evidence]
• wound healing [Insufficient Evidence]
• wrinkled skin [Insufficient Evidence]